Targeting Key Signaling Pathways in Glioblastoma Stem Cells for the Development of Efficient Chemo- and Immunotherapy.
MYC
NF-κB
NK-cells
cancer stem cells
chemotherapy
glioblastoma multiforme
immunotherapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Oct 2022
26 Oct 2022
Historique:
received:
02
09
2022
revised:
23
09
2022
accepted:
21
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is the most aggressive and most common malignant brain tumor with poor patient survival despite therapeutic intervention. On the cellular level, GBM comprises a rare population of glioblastoma stem cells (GSCs), driving therapeutic resistance, invasion, and recurrence. GSCs have thus come into the focus of therapeutic strategies, although their targeting remains challenging. In the present study, we took advantage of three GSCs-populations recently established in our lab to investigate key signaling pathways and subsequent therapeutic strategies targeting GSCs. We observed that NF-κB, a crucial transcription factor in GBM progression, was expressed in all CD44
Identifiants
pubmed: 36361720
pii: ijms232112919
doi: 10.3390/ijms232112919
pmc: PMC9659205
pii:
doi:
Substances chimiques
NF-kappa B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Brain Pathol. 2012 Mar;22(2):159-74
pubmed: 21790828
Cancer Immunol Res. 2014 Sep;2(9):823-30
pubmed: 25187272
J Immunol. 2009 Mar 15;182(6):3530-9
pubmed: 19265131
Cancer Commun (Lond). 2019 Dec 3;39(1):81
pubmed: 31796105
Neuro Oncol. 2009 Jun;11(3):281-91
pubmed: 18952979
Proc Natl Acad Sci U S A. 1990 Jun;87(12):4727-31
pubmed: 2191300
Immunity. 2004 Jul;21(1):19-30
pubmed: 15345217
Cancers (Basel). 2021 Mar 06;13(5):
pubmed: 33800955
Cancers (Basel). 2019 May 11;11(5):
pubmed: 31083587
Sci Rep. 2013;3:1160
pubmed: 23362460
J Exp Med. 1992 Sep 1;176(3):787-92
pubmed: 1512542
Am J Pathol. 1997 Oct;151(4):891-6
pubmed: 9327720
Int J Mol Sci. 2021 Aug 18;22(16):
pubmed: 34445612
Mol Cancer. 2021 Jan 18;20(1):16
pubmed: 33461590
Semin Cancer Biol. 2006 Aug;16(4):318-30
pubmed: 16934487
Int J Mol Med. 2007 May;19(5):809-16
pubmed: 17390087
Biomedicines. 2017 Jun 09;5(2):
pubmed: 28598356
Trends Cancer. 2020 Mar;6(3):223-235
pubmed: 32101725
Pigment Cell Res. 2006 Aug;19(4):290-302
pubmed: 16827748
Sci Rep. 2020 Dec 14;10(1):21858
pubmed: 33318498
Cancers (Basel). 2022 May 09;14(9):
pubmed: 35565467
Int J Cancer. 2008 Mar 15;122(6):1391-9
pubmed: 18000822
Mod Pathol. 2002 Feb;15(2):159-66
pubmed: 11850545
Cells. 2021 Apr 27;10(5):
pubmed: 33925297
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Oncotarget. 2016 Oct 25;7(43):69173-69187
pubmed: 27732951
Front Oncol. 2015 Jul 20;5:159
pubmed: 26258069
Cancer Res. 2008 Feb 1;68(3):650-6
pubmed: 18245463
Cold Spring Harb Symp Quant Biol. 2008;73:427-37
pubmed: 19150964
Genes Dev. 2008 Oct 15;22(20):2755-66
pubmed: 18923074
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Clin Cancer Res. 2016 Sep 1;22(17):4452-65
pubmed: 27076630
Blood. 1997 Dec 15;90(12):5013-21
pubmed: 9389721
PLoS One. 2008;3(11):e3769
pubmed: 19020659
Stem Cells. 2013 May;31(5):857-69
pubmed: 23307586
Radiother Oncol. 2017 Apr;123(1):106-111
pubmed: 28302331
Curr Opin Neurol. 2013 Dec;26(6):701-7
pubmed: 24152818
Glia. 2009 May;57(7):724-33
pubmed: 18985733
Asian Pac J Cancer Prev. ;18(1):3-9
pubmed: 28239999
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Blood. 2013 May 2;121(18):3599-608
pubmed: 23487023
J Neurochem. 2018 Mar;144(6):780-790
pubmed: 29480969
Anticancer Res. 2004 May-Jun;24(3b):1861-71
pubmed: 15274367
Biomedicines. 2018 Apr 17;6(2):
pubmed: 29673141
Neuro Oncol. 2012 Dec;14(12):1452-64
pubmed: 23132408
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Br J Cancer. 1992 Jul;66(1):106-12
pubmed: 1322154
Biomedicines. 2022 Jan 25;10(2):
pubmed: 35203471
Cancers (Basel). 2018 Dec 18;10(12):
pubmed: 30567306
Cancers (Basel). 2020 Sep 10;12(9):
pubmed: 32927768
Stem Cells Dev. 2010 Aug;19(8):1175-82
pubmed: 20222827
Drugs. 2009;69(7):859-88
pubmed: 19441872
Cancers (Basel). 2021 Aug 29;13(17):
pubmed: 34503178
EMBO Rep. 2021 Aug 4;22(8):e52032
pubmed: 34105235
Int J Mol Sci. 2022 Jan 24;23(3):
pubmed: 35163235
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Surg Neurol. 1999 May;51(5):536-42
pubmed: 10321885
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
Adv Sci (Weinh). 2020 Mar 12;7(9):1902971
pubmed: 32382477
iScience. 2021 Dec 01;24(12):103538
pubmed: 34917906
Sci Rep. 2020 Aug 7;10(1):13352
pubmed: 32770097
Genes Dev. 2019 Jun 1;33(11-12):591-609
pubmed: 31160393
Int J Mol Sci. 2020 Oct 20;21(20):
pubmed: 33092025
J Neurosurg. 2013 Dec;119(6):1415-23
pubmed: 24093630
Medicine (Baltimore). 2016 Mar;95(9):e2583
pubmed: 26945349
N Engl J Med. 2011 Feb 17;364(7):627-37
pubmed: 21175304
Math Med Biol. 2012 Mar;29(1):49-65
pubmed: 20610469
Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S2-8
pubmed: 27668386
Mol Cell Biol. 1994 Feb;14(2):1039-44
pubmed: 8289784
Front Immunol. 2018 Jun 18;9:1345
pubmed: 29967607
Ir J Med Sci. 2021 Feb;190(1):41-57
pubmed: 32607912
Stem Cell Res Ther. 2021 Mar 24;12(1):206
pubmed: 33762015
Cancer Res. 2012 Feb 1;72(3):576-80
pubmed: 22298594
J Exp Med. 1992 May 1;175(5):1181-94
pubmed: 1314883
Sci Rep. 2016 Jan 11;6:18772
pubmed: 26752044
Cancer Res. 2004 Oct 1;64(19):7011-21
pubmed: 15466194
Mol Cell. 2002 Dec;10(6):1283-94
pubmed: 12504005
Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56
pubmed: 24137015
Scand J Immunol. 2022 Aug;96(2):e13201
pubmed: 35778892
Mol Cancer. 2020 Aug 6;19(1):120
pubmed: 32762681
Cell. 2020 Jun 25;181(7):1626-1642.e20
pubmed: 32470397
Neuro Oncol. 2009 Oct;11(5):477-87
pubmed: 19139420
Signal Transduct Target Ther. 2022 Feb 9;7(1):37
pubmed: 35136034
Ann Neurol. 2010 Aug;68(2):264-9
pubmed: 20695020
Neurosci Lett. 2003 Mar 13;339(1):62-6
pubmed: 12618301
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046